Method for determining abnormality in particle analyzer and particle analyzer
10151696 ยท 2018-12-11
Assignee
Inventors
Cpc classification
G01N21/6428
PHYSICS
G01N15/1425
PHYSICS
G01N2015/1402
PHYSICS
International classification
G01N35/00
PHYSICS
Abstract
Disclosed is a method for determining abnormality in a particle analyzer. The method includes: staining first control particles but not staining second control particles which emit fluorescence; irradiating with light the first control particles and the second control particles flowing in a flow cell, and detecting fluorescence from the first control particles and the second control particles; obtaining a first management value indicating a detection result of the fluorescence emitted from the first control particles and a second management value indicating a detection result of the fluorescence emitted from the second control particles; and determining abnormality in the staining step, based on a value calculated from the first management value and the second management value or a ratio between the first management value and the second management value.
Claims
1. A method performed by a particle analyzer for determining an abnormality in a particle analysis process carried out by the particle analyzer, the method comprising: mixing first control particles and fluorescence emitting second control particles with a fluorescent stain in a specimen preparation unit, wherein the first control particles react with the fluorescent stain and the second control particles do not react with the fluorescent stain; irradiating the first control particles and the second control particles flowing in a flow cell with light, and detecting fluorescence from the first control particles and the second control particles; obtaining a first management value indicating a detection result of the fluorescence emitted from the first control particles and a second management value indicating a detection result of the fluorescence emitted from the second control particles, wherein the first management value is based on an intensity of detected fluorescence from the first control particles, and the detection result is related to an abnormality in the specimen preparation unit or detecting fluorescence from the first control particles, and wherein the second management value is based on an intensity of detected fluorescence from the second control particles, and the detection result is related to an abnormality in detecting fluorescence from the second control particles; calculating a third management value by dividing the first management value and the second management value, or a ratio of the first management value and the second management value by an analysis unit that determines an abnormality in specimen preparation of the first control particles and the second control particles when the third management value or the ratio of the first and second management values is outside of an upper threshold and a lower threshold; and displaying, on an output unit, a screen showing a message to suggest replacement of the fluorescent stain when an abnormality is determined based on the third management value or the ratio.
2. The method for determining abnormality of claim 1, further comprising determining abnormality in the detecting fluorescence from the first control particles and the second control particles based on the second management value.
3. The method for determining abnormality of claim 1, further comprising prohibiting measurement on a clinical sample by the particle analyzer in a case where the second management value indicates abnormality and in a case where the ratio or the third management value is outside of the upper threshold and lower threshold.
4. The method for determining abnormality of claim 1, further comprising displaying a list including: an abnormality determination result based on the second management value; and an abnormality determination result based on one of the ratio or the third management value.
5. The method for determining abnormality of claim 1, wherein the first control particles are selected from the group consisting of cells, polyacrylamide particles, hydrophilic vinyl polymer particles, latex particles, and silica particles.
6. The method for determining abnormality of claim 1, wherein the first control particles are cells, and nuclei of the cells are stained with the fluorescent stain.
7. The method for determining abnormality of claim 6, further comprising contacting the first control particles with RNA remover.
8. The method for determining abnormality of claim 7, wherein, in a case where the third management value is smaller than the lower threshold, it is determined that there is abnormality in the fluorescent stain, and in a case where the third management value is greater than the upper threshold, it is determined that there is abnormality in the RNA remover.
9. The method for determining abnormality of claim 1, wherein the particle analyzer analyzes an amount of DNA of each of cells contained in a sample.
10. The method for determining abnormality of claim 1, wherein the particle analyzer analyzes an amount of DNA of each of cells contained in a sample to calculate a number of cells containing a predetermined amount or more of DNA.
11. The method for determining abnormality of claim 1, wherein the first management value is a value based on a representative value of a numerical value obtained from waveforms of fluorescence signals of the respective first control particles, and the second management value is a value based on a representative value of a numerical value obtained from waveforms of fluorescence signals of the respective second control particles.
12. A method performed by a particle analyzer for determining abnormality in a particle analysis process carried out by the particle analyzer which analyzes, based on a signal waveform of fluorescence emitted from a fluorescence-stained cell nucleus, an amount of DNA contained in the cell nucleus, the method comprising: mixing first control particles and fluorescence emitting second control particles with a fluorescent stain in a specimen preparation unit, wherein the first control particles react with the fluorescent stain and the second control particles do not react with the fluorescent stain; irradiating with light the first control particles and the second control particles flowing in a flow cell, and obtaining signal waveforms based on fluorescence from each first control particle and each second control particle; obtaining a representative value of an area of a signal waveform of the fluorescence from each first control particle as a first fluorescence area, wherein the first fluorescence area is based on an intensity of detected fluorescence from the first control particles and is related to an abnormality in the specimen preparation unit or detecting fluorescence from the first control particles; obtaining a representative value of an area of the signal waveform of the fluorescence from each second control particle as a second fluorescence area, wherein the second fluorescence area is based on an intensity of detected fluorescence from the second control particles and is related to an abnormality in detecting fluorescence from the second control particles; calculating a ratio of the first and second fluorescence areas by an analysis unit that determines an abnormality in staining performed in the particle analyzer when the ratio is outside of an upper threshold and a lower threshold; and displaying, on an output unit, a screen showing a message to suggest replacement of the fluorescent stain when an abnormality is determined based on the ratio.
13. The method for determining abnormality of claim 12, wherein the first control particles are cells.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
(1)
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
(10)
(11)
(12)
(13)
(14)
(15)
(16)
(17)
(18)
(19)
(20)
(21)
(22)
(23)
(24)
(25)
(26)
(27)
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
(28) Embodiments 1 and 2 below are applied to an apparatus whose analysis target is uterine cervix cells and which obtains information regarding canceration of the cells. The analysis target may be buccal cells, epithelial cells of the bladder, the pharynx, or the like, or epithelial cells of organs.
Embodiment 1
(29) As shown in
(30) First, a case where the operation mode is the normal mode will be described. The sample 11 is a liquid in which cells are suspended in a preservative liquid whose principal component is alcohol. The sample 11 is contained in a sample container. Preferably, the alcohol is methanol. The transfer unit 20 aspirates the sample 11, dispenses the aspirated sample 11 into a cuvette not shown, and transfers the cuvette. The pretreatment unit 30 disperses, with ultrasonic waves, aggregated cells contained in the sample 11 dispensed in the cuvette. Further, the pretreatment unit 30 replaces the preservative liquid suspending the cells contained in the sample 11, with a diluent. The pretreatment unit 30 removes contaminant from the sample 11 and concentrates the sample 11.
(31) The specimen preparation unit 40 mixes reagents 41 and 42 and the sample 11 having been subjected to the processing by the pretreatment unit 30, to prepare a mixture. The reagent 41 contains a fluorescent dye. The fluorescent dye contained in the reagent 41 is a nucleic acid staining dye. Nucleic acid in each cell contained in the sample 11 is stained by the reagent 41.
(32) It is sufficient that the nucleic acid staining dye is a fluorescent dye which emits fluorescence by binding to nucleic acid. An example of the nucleic acid fluorescent dye is propidium iodide, ethidium bromide, ethidium-acridine heterodimer, ethidium diazide, ethidium homodimer-1, ethidium homodimer-2, ethidium monoazide, trimethylenebis[[3-[[4-[[(3-methyl benzothiazole-3-ium)-2-yl]methylene]-1,4-dihydroquinoline]-1-yl]propyl]dimethylaminium]tetraiodide, 4-[(3-methylbenzothiazole-2(3H)-ylidene)methyl]-1-[3-(trimethylaminio) propyl]quinolinium diiodide, N,N,N,N-tetramethyl-N,N-bis[3-[4-[3-[(3-methylbenzothiazole-3-ium)-2-yl]-2-propenylidene]-1,4-dihydroquinoline-1-yl]propyl]-1,3-propanediaminium tetraiodide, or 2-[3-[[1-[3-(trimethylaminio) propyl]-1,4-dihydroquinoline]-4-ylidene]-1-propenyl]-3-methylbenzothiazol-3-ium diiodide.
(33) The reagent 42 contains an RNA remover for removing RNA contained in the sample 11. The sample 11 sometimes contains RNA in the cells. Since the reagent 41 is a nucleic acid staining dye, there are cases where the reagent 41 stains RNA contained in the sample 11. When RNA is stained, RNA-derived fluorescence is added to DNA-derived fluorescence to be detected, causing increased background, which is not preferable. Such RNA is degraded by the reagent 42.
(34) The optical detection unit 50 includes a flow cytometer. The optical detection unit 50 causes the mixture prepared by the specimen preparation unit 40 to flow in a flow cell 50a. The optical detection unit 50 irradiates with light the mixture flowing in the flow cell 50a. The optical detection unit 50 detects light emitted from the mixture.
(35) As shown in
(36) The light source 51 emits a laser beam. The condenser lens group 52 is composed of a plurality of lenses. The condenser lens group 52 condenses the laser beam on the mixture flowing in the flow cell 50a. Accordingly, from the particles in the mixture, forward scattered light and fluorescence are generated. Forward scattered light reflects the size of each particle, and fluorescence reflects the degree of staining of the particle.
(37) The condenser lens 53 condenses forward scattered light. The optical detector 54 receives forward scattered light. The optical detector 54 is a photodiode. The optical detector 54 outputs an electric signal corresponding to the received forward scattered light, i.e., a forward scattered light signal. The condenser lens 55 condenses fluorescence. The optical detector 56 receives fluorescence. The optical detector 56 is a photomultiplier. The optical detector 56 outputs an electric signal corresponding to the received fluorescence, i.e., a fluorescence signal.
(38) The signal processing circuit 57 performs predetermined signal processing on signals outputted from the optical detectors 54 and 56, to obtain waveforms corresponding to the forward scattered light signal and the fluorescence signal, respectively. The signal processing circuit 57 calculates a plurality of characteristic parameters such as the peak value, the width, and the area, from each obtained waveform. As shown in
(39) With reference back to
(40) Next, a case where the operation mode is the quality control mode will be described. The first control particles 12a are particles to be stained by the fluorescent dye of the reagent 41. The second control particles 12b are particles which are substantially not stained by the fluorescent dye of the reagent 41, and which emit fluorescence by containing a fluorescent dye in advance.
(41) The first control particles 12a are selected from the group consisting of: cells, polyacrylamide particles, hydrophilic vinyl polymer particles, latex particles, and silica particles. Preferably, the first control particles 12a are cells.
(42) The second control particles 12b are fluorescent latex particles. The second control particles 12b emit fluorescence more intense than that emitted by the first control particles 12a. More specifically, the second control particles 12b emit fluorescence more intense than that emitted by the first control particles 12a which have been stained under an appropriate condition by use of the reagents 41 and 42. Thus, based on the difference between the fluorescence intensities, the first control particles 12a can be distinguished from the second control particles 12b.
(43) The first control particles 12a and the second control particles 12b are contained in containers, respectively. The transfer unit 20 aspirates the first control particles 12a and the second control particles 12b, dispenses them into cuvettes not shown, and transfers the cuvettes. The pretreatment unit 30 is not used in the quality control mode. The specimen preparation unit 40 mixes the first control particles 12a, the second control particles 12b, and the reagents 41 and 42, to prepare a mixture. Accordingly, the first control particles 12a are stained by the reagent 41.
(44) The first control particles 12a contain RNA in the specimen. This is for determining whether the reagent 42 containing the RNA remover is properly acting or not.
(45) As in the normal mode, the optical detection unit 50 causes the mixture prepared by the specimen preparation unit 40 to flow in the flow cell 50a. The optical detection unit 50 irradiates with light the first control particles 12a and the second control particles 12b flowing in the flow cell 50a. The optical detection unit 50 detects light emitted from each of the first control particles 12a and the second control particles 12b. The signal processing circuit 57 of the optical detection unit 50 outputs, to the analysis unit 60, characteristic parameters of each light of each particle. The analysis unit 60 stores, in the storage 60a, the characteristic parameters of each light of each particle outputted from the signal processing circuit 57.
(46) Based on the characteristic parameters of each light of each particle, the analysis unit 60 obtains a first management value, a second management value, and a third management value. The first management value and the second management value represent detection results of fluorescence emitted from the first control particles 12a and the second control particles 12b, respectively. The third management value is a value calculated from the first management value and the second management value. Based on the second management value, the analysis unit 60 determines detection abnormality, i.e., abnormality in the optical detection unit 50. Based on the third management value, the analysis unit 60 determines staining abnormality, i.e., abnormality in staining performed in the specimen preparation unit 40. When there are detection abnormality and staining abnormality, the analysis unit 60 outputs notifications of the respective detection abnormality and staining abnormality via the output unit 70. How to determine detection abnormality and staining abnormality will be described later with reference to flow charts.
(47) Next, the process performed by the particle analyzer 10 in the normal mode will be described with reference to the flow chart shown in
(48) As shown in
(49) In step S105, based on the characteristic parameters of each light of each particle stored in the storage 60a, the analysis unit 60 extracts cells whose N/C ratio is within a predetermined range from among all the cells contained in the mixture. By calculating the width of the waveform of a fluorescence signal/the width of the waveform of a forward scattered light signal, the analysis unit 60 obtains the N/C ratio. Instead of the N/C ratio, the analysis unit 60 may calculate the C/N ratio, and may extracts cells whose C/N ratio is within a predetermined range.
(50) Next, in step S106 and S107, the analysis unit 60 performs analysis based on the amount of DNA of each of cells contained in the sample 11 as described below. In step S106, the analysis unit 60 creates a histogram regarding the amount of DNA of the cells extracted in step S105. Specifically, the analysis unit 60 creates a histogram whose two axes represent the area of waveform of fluorescence signal and the number of cells. The area of the waveform of a fluorescence signal (hereinafter, referred to as fluorescence area) corresponds to the amount of DNA of the cell. In step S107, the analysis unit 60 analyses the fluorescence areas of the cells contained in the sample 11, to obtain the ratio of cells each containing a predetermined amount or more of DNA (hereinafter, referred to as target cell ratio). Specifically, based on the histogram created in step S106, the analysis unit 60 calculates the number of cells each having a fluorescence area greater than or equal to a predetermined threshold/the number of cells each having a fluorescence area less than the predetermined threshold, to obtain a target cell ratio.
(51) Here, for convenience of explanation, the target cell ratio is obtained by creating a histogram in step S106, but it is not necessary to actually create a histogram. That is, the target cell ratio may be obtained through data processing based on the cells extracted in step S105. Similarly, also in step S204 in
(52) In step S108, based on the target cell ratio obtained in step S107, the analysis unit 60 determines whether retesting is necessary or not. When the target cell ratio is greater than or equal to a predetermined value, the analysis unit 60 determines that retesting is necessary. When the target cell ratio is less than the predetermined value, the analysis unit 60 determines that retesting is not necessary. In step S109, the analysis unit 60 displays, on the output unit 70, the target cell ratio and the determination result indicating whether retesting is necessary or not, as the analysis result.
(53) In the particle analyzer 10 which performs analysis based on the amount of DNA, staining of nucleic acid by the reagent 41 and reduced background by the reagent 42 have direct influence on the shape of the histogram regarding the amount of DNA. The reagent 41 and the reagent 42 may deteriorate due to storage condition and use condition. When the reagent 41 is deteriorated, nucleic acid is not sufficiently stained. This may case the distribution of the histogram to be shifted toward the low value side. When the reagent 42 is deteriorated, RNA is not sufficiently removed, and background of fluorescence is increased. This may cause the distribution of the histogram to be shifted toward the high value side. Either case could have unfavorable influence on accurate analysis of the amount of DNA.
(54) Therefore, quality management of the reagents 41 and 42 is important, and further, it is important to determine staining abnormality in the specimen preparation unit 40 in the quality control mode.
(55) Next, the process performed by the particle analyzer 10 in the quality control mode will be described with reference to the flow chart shown in
(56) As shown in
(57) In step S204, the analysis unit 60 obtains a first measurement value and a second measurement value. Specifically, first, based on the difference in fluorescence intensities, the analysis unit 60 classifies data of each particle stored in the storage 60a, as either the first control particle 12a or the second control particle 12b. As described above, the second control particles 12b emit fluorescence more intense than that emitted by the first control particles 12a. Therefore, based on the difference in fluorescence intensities, classification between the first control particles 12a and the second control particles 12b can be performed.
(58) Next, with respect to each type of the first control particles 12a and the second control particles 12b, as shown in
(59) In step S205, based on a predetermined number of times of measurements, the analysis unit 60 determines whether the quality control measurement has ended. When it is assumed that the predetermined number of times of measurements is n, the analysis unit 60 repeats the processes of steps S202 to S204 n times. When it is assumed that the n-th first measurement value is V1n and the n-th second measurement value is V2n, the analysis unit 60 obtains a first measurement value and a second measurement value in each of the first to n-th measurements as shown in
(60) In the above procedure, the reagents 41 and 42, the first control particles 12a, and the second control particles 12b are mixed together to prepare a mixture. However, instead of this, a mixture of the first control particles 12a and a mixture of the second control particles 12b may be separately prepared. In this case, the processes of steps S202 to S205 are replaced with steps S221 to S228, as shown in
(61) As shown in
(62) Next, in steps S225 to S228, as in steps S221 to S224, the analysis unit 60 obtains the second measurement values the predetermined number of times. Also through steps S221 to S228 in
(63) With reference back to
First management value=(V11+V12+ . . . +V1n)/n(11)
Second management value=(V21+V22+ . . . +V2n)/n(12)
Third management value=first management value/second management value(13)
(64) The second management value is a value obtained based on fluorescence generated from the second control particles 12b which are substantially not stained by the reagent 41 and which contain a fluorescent dye in advance. Thus, the second management value reflects the state of the optical detection unit 50. In contrast, the first management value is a value that also reflects the state (such as reagent deterioration) of the staining step in addition to the state of the optical detection unit 50. The first management value can be considered as the product of the second management value representing the state of the optical detection unit 50 and the value representing the state of the staining step. Therefore, the third management value obtained by dividing the first management value by the second management value reflects the state of the staining step.
(65) The third management value may be a value obtained by squaring the first management value/the second management value. The third management value may be a value obtained by adding a constant to the first management value/the second management value, subtracting a constant from the first management value/the second management value, multiplying the first management value/the second management value with a constant, or dividing the first management value/the second management value by a constant. The third management value may be the second management value/the first management value. The third management value may be a value of a log of the first management value/the second management value. The third management value may be obtained by (V11+V12+ . . . +V1 n)/(V21+V22+ . . . +V2n), without using the first management value and the second management value. The third management value may not be a value based on the ratio between the first management value and the second management value. For example, the ratio of the first management value to a target value 1 of the first management value (first management value/target value 1) and the ratio of the second management value to a target value 2 of the second management value (second management value/target value 2) are calculated, and then, the difference between these ratios may be used as the third management value.
(66) In step S207, based on the second management value and the third management value, the analysis unit 60 performs the processes of abnormality determinations shown in
(67) As shown in
(68) As shown in
(69) The staining abnormality determination may be a process shown in
(70) As shown in
(71) Here, for convenience of explanation, in step S421, a point based on the first management value and the second management value is plotted on the coordinate space, but it is not necessary to actually create the coordinate space and plot the point. That is, instead of creating the coordinate space, plotting the point, and determining whether the plotted point is within the normal range, whether the point based on the first management value and the second management value is within the normal range may be determined by data processing.
(72) The process of abnormality determination is performed in accordance with separate flow charts as shown in
(73) With reference back to
(74) When having determined as NO in step S208 and having determined as NO in step S209, then, in step S211, the analysis unit 60 displays a screen 71 as shown in
(75) When having determined as NO in step S208 and having determined as YES in step S209, then, in step S212, the analysis unit 60 displays a screen 72 as shown in
(76) In step S213, the analysis unit 60 prohibits measurement on the sample 11 in the normal mode. Accordingly, the processes of step S102 and thereafter in
(77) When having determined as YES in step S208 and having determined as NO in step S210, then, in step S214, the analysis unit 60 displays a screen 73 as shown in
(78) When having determined as YES in step S208 and having determined as YES in step S210, then, in step S215, the analysis unit 60 displays a screen 74 as shown in
(79) In step S215, even in the case where there is abnormality in both the optical detection unit 50 and the specimen preparation unit 40, notifications of detection abnormality and reagent abnormality are individually and assuredly made. Accordingly, the operator can smoothly and quickly take measures for eliminating the abnormalities, and thus, the operator can smoothly and quickly eliminate the detection abnormality and the reagent abnormality.
(80)
(81) Every time the analysis unit 60 obtains a third management value in the quality control mode, the analysis unit 60 may store the obtained third management value in the storage 60a. In this case, by observing the change in the third management value over time, it is possible to predict deterioration of the reagents 41 and 42, and to predict replacing time of the reagents 41 and 42.
Embodiment 2
(82) In Embodiment 2, the configuration of the particle analyzer 10 is the same as that in Embodiment 1, and only the process of staining abnormality determination is different from that in Embodiment 1, as described below.
(83) As shown in
(84) When having determined as NO in step S441 and having determined as NO in step S442, then, in step S443, the analysis unit 60 determines that there is no staining abnormality. When having determined as NO in step S441 and having determined as YES in step S442, then, in step S444, the analysis unit 60 determines that there is abnormality in the reagent 41. When having determined as YES in step S441, then in step S445, the analysis unit 60 determines that there is abnormality in the reagent 42. The analysis unit 60 may perform the determination in steps S441 and S442 by use of the coordinate space shown in
(85) When it has been determined that there is abnormality in a reagent in step S444, S445, a message urging replacement of the reagent is displayed in a later stage of step S212, S215 in
(86) Here, the case where it is determined that there is staining abnormality in the process of the staining abnormality determination in Embodiment 1 shown in
(87) Thus, according to Embodiment 2, as in Embodiment 1, it is possible to determine that there is staining abnormality, and further, it is possible to know which of the reagents 41 and 42 should be replaced.
(88) <Experiment Regarding Abnormality Determination>
(89) Next, an experiment actually conducted regarding abnormality determination will be described.
(90) 1. Material
(91) The first control particles 12a, the second control particles 12b, the reagent 41, and the reagent 42 used in the experiment were as follows.
(92) The first control particles 12a were prepared as follows. [C33A Cells (HTB-31)] available from American Type Culture Collection were suspended in [PreservCyt] available from Hologic Inc. and left still for 24 hours. Then, the mixture was centrifuged to remove the supernatant. The resultant mixture was suspended in pH7.5, 10 mM Tris hydrochloric acid aqueous solution. This final mixture was used as the first control particles 12a. As the second control particles 12b, [AlignFlow Plus Flow Cytometry Alignment Beads (A-7303)] available from Life Technologies Inc. diluted by pH7.5, 10 mM Tris hydrochloric acid aqueous solution were used.
(93) As the reagent 41, [Propidium Iodide (PI)] available from Sigma-Aldrich Co. LLC. diluted by ethylene glycol was used. The reagent 41 was prepared in two types. That is, after the reagents 41 were prepared, one was stored with light blocked and the other was stored under exposure to light. Thus, the reagent 41 stored with light blocked, and the reagent 41 stored under exposure to light to be deteriorated were used as the reagent 41. As the reagent 42, [RNaseA (Cat. R4642)] available from Sigma-Aldrich Co. LLC. diluted by pH7.5, 10 mM Tris hydrochloric acid aqueous solution was used.
(94) 2. Condition
(95) In the experiment, in order to reproduce abnormality in the reagent 41 being a stain liquid and sensitivity abnormality in the optical detection unit 50, the reagent 41 and the voltage applied to the optical detector 56 which detects fluorescence were changed in accordance with the following three conditions.
(96) Condition 1: the reagent 41 was the one stored under exposure to light; and the voltage applied to the optical detector 56 was 251 V, which was an appropriate voltage.
(97) Condition 2: the reagent 41 was the one stored under exposure to light; and the voltage applied to the optical detector 56 was 255 V.
(98) Condition 3: the reagent 41 was the one stored with light blocked; and the voltage applied to the optical detector 56 was 253 V.
(99) 3. Experiment Procedure
(100) In the experiment, measurement regarding the first control particles 12a and measurement regarding the second control particles 12b were separately performed. That is, in the flow chart shown in
(101) In step S221 in
(102) Next, in step S225 of
(103) The first measurement values and the second measurement values obtained under Conditions 1 to 3 are shown in the upper tables in
(104) Next, in step S206 in
(105) The upper limit thresholds and the lower limit thresholds used in determination on the first to third management values were set as shown in
(106) Next, system abnormality determination, detection abnormality determination, and staining abnormality determination were performed. The detection abnormality determination and the staining abnormality determination were performed in accordance with the processes shown in
(107) 4. Experiment Result
(108) As shown in the lower tables in
(109) The experiment above has revealed that, under Condition 1 using the reagent 41 stored under exposure to light, even though the determinations on the first management value and the second management value were both G, i.e., there was no abnormality in the system and the detection, the determination on the third management value was NG, i.e., there was abnormality in staining. This abnormality is the one that cannot be found by the technique of U.S. Patent Application Publication No. 2007/013906 which focuses only on the amount of fluorescence of the first control particles 12a (first management value) and the amount of fluorescence of the second control particles 12b (second management value).
(110) In this point, according to the techniques in Embodiments 1 and 2, the third management value representing the staining state is obtained separately from the first management value, whereby it is possible to find abnormality in the staining step which was not grasped conventionally. By replacing the relevant reagent to cause the third management value to be within the reference range, the operator can perform maintenance such that appropriate DNA amount analysis can be performed.
(111) In Conditions 2 and 3, the determinations on the first management value were the same with each other, and the determinations on the second management value were the same with each other. However, under Condition 2 using the reagent 41 stored under exposure to light, the determination on the third management value was NG, i.e., that there was abnormality in staining was shown. Under Condition 3 using the reagent 41 stored with light blocked, the determination on the third management value was G, i.e., that there was no abnormality in staining was shown. The difference in the determination between Condition 2 and Condition 3 cannot be found either, by the technique of U.S. Patent Application Publication No. 2007/013906 which focuses only on the amount of fluorescence of the first control particles 12a (first management value) and the amount of fluorescence of the second control particles 12b (second management value).
(112) The technique of U.S. Patent Application Publication No. 2007/013906 does not provide indices for determining a case where the second management value indicates abnormality, i.e., a case there is abnormality in the optical detection unit, and further, for determining whether there is abnormality also in the staining step. In the case where there is abnormality in both of the optical detection unit and the staining step, the operator performs reagent replacement in addition to sensitivity adjustment of the optical detection unit. However, with the conventional technique, whether the abnormality requires reagent replacement is unknown.
(113) In this point, according to the techniques of Embodiments 1 and 2, based on the third management value which is the value of the ratio of the first management value to the second management value, detection abnormality and staining abnormality can be separately determined. Therefore, it is seen that staining abnormality that cannot be determined from the first management value and the second management value can be determined by use of the third management value. Thus, it is seen that, according to Embodiments 1 and 2, even in the case where there is abnormality in both of the optical detection unit 50 and the specimen preparation unit 40, it is possible to individually and assuredly make notifications of the detection abnormality and the reagent abnormality.